Evidence map›Paper›PMID 42343673›Full record

ArticlemAbs2026

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

Matthew Saunders, Sophie Comyn, Borka Medjo, Zahra Anderson, Chase LaCombe, Jake Ripley, Kyra Chapman, Tim Ma, Abigail Ventura, Alyssa Ruelos and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Matthew SaundersBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Sophie ComynBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Borka MedjoBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Zahra AndersonBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Chase LaCombeBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Jake RipleyBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Kyra ChapmanBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Tim MaBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Abigail VenturaBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Alyssa RuelosBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Alec JaegerBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Chase PoindexterBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Ophelia RebanalBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Nemanja VuvicBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
Sean M WestBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
David EavaroneBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
John M SuttonAI Research and Engineering, Absci Corporation, Vancouver, WA, USA.
Douglas Ganini da SilvaBiologics Discovery Technologies, Absci Corporation, Vancouver, WA, USA.
David A SpencerAI Research and Engineering, Absci Corporation, Vancouver, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody polyreactivity, which is characterized by broad, low-affinity off-target binding, is an undesirable drug property associated with rapid clearance. Existing

Indexed as

Antibodies, MonoclonalAntibody SpecificitySingle-Chain AntibodiesComplementarity Determining RegionsComputer SimulationEnzyme-Linked Immunosorbent AssayHigh-Throughput Screening AssaysHumansAntibodies, MonoclonalComplementarity Determining RegionsSingle-Chain AntibodiesAntibodiesdevelopabilitymachine learningoptimizationpolyreactivity

Identifiers

PMID42343673
PMCPMC13313185

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.